14.48

2.99% 0.41

Rigel Pharmaceuticals (RIGL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rigel Pharmaceuticals stock is traded at $14.48, with a volume of 26,817. It is up +2.99% in the last 24 hours and down -9.66% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Previous Close:

$14.07

Open:

$14.1

24h Volume:

26,817

Relative Volume:

0.20

Market Cap:

$254.78M

Revenue:

$116.88M

Net Income/Loss:

$-25.09M

P/E Ratio:

-65.82

EPS:

-0.22

Net Cash Flow:

$-20.74M

1W Performance:

+1.05%

1M Performance:

-9.66%

6M Performance:

+20.75%

1Y Performance:

+64.45%

1-Day Range:

$13.91

$14.57

1-Week Range:

$13.57

$14.57

52-Week Range:

$7.4843

$17.30

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name

Rigel Pharmaceuticals

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

650-624-1100

Address

611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA

Employee

147

Twitter

@rigelpharma

Next Earnings Date

2024-11-07

Latest SEC Filings

RIGL's Discussions on Twitter

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-23	Resumed	Piper Sandler	Neutral
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-23-22	Initiated	B. Riley Securities	Neutral
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight
Sep-26-19	Resumed	JP Morgan	Overweight
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight
Aug-27-18	Initiated	Citigroup	Buy
May-02-18	Reiterated	Cantor Fitzgerald	Overweight
Dec-21-17	Resumed	Piper Jaffray	Overweight
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight
Nov-06-17	Resumed	H.C. Wainwright	Buy
Mar-09-17	Reiterated	H.C. Wainwright	Buy
Aug-31-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Reiterated	Piper Jaffray	Overweight
Jul-13-16	Initiated	H.C. Wainwright	Buy
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight
Apr-08-13	Reiterated	Stifel	Buy
Nov-29-12	Initiated	UBS	Neutral
Nov-06-12	Reiterated	Oppenheimer	Outperform
Mar-26-12	Initiated	Canaccord Genuity	Hold
Dec-10-10	Downgrade	MP Advisors	Outperform → Market Perform

View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

09:05 AM

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire

09:05 AM

Nov 03, 2024

Certain Stock Options of Rigel Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2018. - Marketscreener.com

Nov 03, 2024

Nov 01, 2024